Published in:
01-09-2019 | Ovarian Hyperstimulation Syndrome | Gynecologic Endocrinology and Reproductive Medicine
Effect of pretreatment with combined oral contraceptives on outcomes of assisted reproductive technology for women with polycystic ovary syndrome: a meta-analysis
Authors:
Soo Youn Song, Jung Bo Yang, Min Soon Song, Hye Young Oh, Geon Woo Lee, Mina Lee, Young Bok Ko, Ki Hwan Lee, Ha Kyun Chang, Sang Mi Kwak, Heon Jong Yoo
Published in:
Archives of Gynecology and Obstetrics
|
Issue 3/2019
Login to get access
Abstract
Objective
To evaluate the effect of pretreatment with combined oral contraceptives (COC) on outcomes in women with polycystic ovary syndrome (PCOS) who underwent assisted reproductive technology for subfertility.
Methods
Two authors independently searched MEDLINE, EMBASE, and the Cochran Library to identify and review articles published from October 1995 until December 2018 according to selection criteria. Outcomes are expressed as mean difference and odds ratio (OR) in a meta-analysis model.
Results
A total of seven studies were included in this meta-analysis: one randomized controlled study and two prospective and four retrospective cohort studies. Meta-analysis showed that the COC pretreatment did not affect rate of clinical pregnancy (OR = 0.93, 95% confidence interval CI 0.65–1.34, I2 = 76%) or ovarian hyperstimulation syndrome (OR = 0.90, 95% CI 0.57–1.44, I2 = 0%). However, the rate of miscarriage in the COC group was significantly higher (OR = 1.33, 95% CI 1.02–1.72, I2 = 9%) and the rate of cumulative live birth was significantly lower compared with the control group (OR = 0.72, 95% CI 0.54–0.98, I2 = 55%). Subgroup analysis showed higher rates of miscarriage and lower rates of cumulative live birth in studies with a gonadotropin-releasing hormone (GnRH) antagonist protocol (OR = 1.69, 95% CI 1.17–2.44, I2 = 0% and OR = 0.38, 95% CI 0.29–0.50, respectively).
Conclusion
Pretreatment with COC in women with PCOS before assisted reproductive technology may have an adverse effect on clinical outcomes, especially with a GnRH antagonist protocol.